Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1102-1109

  Levitan, Nathan ^a   Dowlati, Afshin ^a   Shina, Donald ^a   Craffey, Mark ^a   Mackay, Wilma ^a   DeVore, Russell ^a   Jett, James ^a   Remick, Scot C ^a   Chang, Alex ^a   Johnson, David ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEVER; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 0033997959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1102     Document Type: Article

References (25)

1. Warde P, Payne D: Dose thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992
2. Pignon JP, Arriagada R, Ihde CE, et al: A meta-analysis of thoracic irradiation for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
3. McCracken JD, Janaki LM, Crowley JJ, et al: Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma: A Southwest Oncology Group study. J Clin Oncol 8:892-898, 1990
4. Turrisi AT, Wagner H, Glover B, et al: Limited small-cell lung cancer (LSCLC): Concurrent BID thoracic radiotherapy (TRT) with platinum-etoposide (PE) - ECOG study. Proc Am Soc Clin Oncol 9:230a, 1990 (abstr 887)
5. Johnson DH, Turrisi AT, Chang AY, et al: Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: A pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 11:879-884, 1993
6. Johnson BE, Bridges JD, Sobczeck M, et al: Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14:806-813, 1996
7. Turrisi AT, Kyungmann K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
8. Albain KS, Crowley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,850-patient Southwest Oncology Group data base. J Clin Oncol 8:1563-1574, 1990
9. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
10. Kirschling RJ, Jung SH, Jett JR, et al: A phase II trial of Taxol and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer. Proc Am Soc Clin Oncol 13:326a, 1994 (abstr 1076)
11. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusions. J Clin Oncol 12:2654-2666, 1994
12. Bunn PA: Defining the role of paclitaxel in lung cancer: Summary of recent studies and implications for future directions. Semin Oncol 24:153-162, 1997 (suppl 12)
13. Bunn PA, Kelly K: A phase I trial of cisplatin, etoposide, and paclitaxel in small-cell lung cancer. Semin Oncol 24:144-148, 1997 (suppl 12)
14. Hainsworth JD, Stroup S, Greco FA: Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer 77:2458-2463, 1996
15. Gatzemeier U, Jagos U, Kaukel E, et al: Paclitaxel, carboplatin and oral etoposide: A phase II trial in limited-stage small-cell lung cancer. Semin Oncol 24:149-152, 1997 (suppl 12)
16. Glisson BS, Kurie JM, Fox NJ, et al: Phase MI study of cisplatin, etoposide and paclitaxel (PET) in patients with extensive small-cell lung cancer. Proc Am Soc Clin Oncol 16:455a, 1997 (abstr 1635)
17. Bremnes RM, Sunstrom S, Aasebo U, et al: Paclitaxel in combination with cisplatin, etoposide and thoracic radiotherapy for limited stage small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol 17:475a, 1998 (abstr 1826)
18. Bezwoda W, Lewis D, Livini N: Bone marrow involvement in anaplastic small-cell lung cancer. Cancer 58:1762-1765, 1986
19. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
20. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD, National Cancer Institute, 1988
21. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. J Clin Oncol 11:336-344, 1993
22. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987
23. Nielsen OS, Fode K, Bentzen SM, et al: Timing of radiotherapy and chemotherapy in limited-stage small-cell lung cancer: Final analysis. Eur J Cancer 2:S182, 1991 (suppl) (abstr)
24. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1852, 1993
25. Glisson B, Scott C, Komaki R, et al: Cisplatin, ifosfamide, prolonged oral etoposide and concurrent accelerated hyperfractionated thoracic radiotherapy for patients with limited small-cell lung cancer: Results of RTOG 93-12. Proc Am Soc Clin Oncol 17:450a, 1998 (abstr 1733)